secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0001641172-25-005777
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi appoints Eric Poma as CEO; Allan Camaisa resigns, remains director
-------------------------------------------------------------------------

- Allan Camaisa resigned as CEO and Chairman, effective April 21, 2025; will stay as Class III director and CEO Emeritus.
- Eric Poma, Ph.D. named CEO and Class I director effective April 22, 2025; previously CEO of Molecular Templates (MTEM).
- Poma receives $535k base salary, target bonus up to 50% of base, and option grant for 726,412 shares vesting over 4 years.
- Camaisa gets $500k separation over 12 months, COBRA for 12 months, $10k/month transition pay, plus possible incentives through Dec 2026.
- James Schoeneck appointed Chairman; board size increased from 5 to 6 members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/0001641172-25-005777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-005777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer